(BIOA) (BIOA) Stock Price, News & Analysis

Company Overview

BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

Key Stats

• Today's Range: $18.11 to $19.18
• 50-Day Range: N/A
• 52-Week Range: $0.01 to $2.88
• Volume: 228,361 shs
• Average Volume: 278,478 shs
• Market Capitalization: $659.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.33
• Consensus Rating: Buy

(BIOA) Stock Analysis - MarketRank™

(BIOA) scored higher than 34% of companies evaluated by MarketBeat, and ranked 776th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

(BIOA) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

(BIOA) has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for (BIOA) are expected to grow in the coming year, from ($3.36) to ($3.22) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BIOA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

(BIOA) does not currently pay a dividend.

Dividend Growth

(BIOA) does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BIOA.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for (BIOA) this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for BIOA on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, (BIOA) insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,205,215.00 in company stock and sold $0.00 in company stock.

BIOA Stock Analysis - Frequently Asked Questions

How were (BIOA)'s earnings last quarter?

(BIOA) (NYSE:BIOA) released its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.02. The biotechnology company had revenue of $2.50 million for the quarter, compared to analyst estimates of $2.37 million.

When did (BIOA) IPO?

(BIOA) (BIOA) raised $198 million in an initial public offering on Thursday, September 26th 2024. The company issued 11,000,000 shares at $18.00 per share.

When did (BIOA)'s quiet period expire?

(BIOA)'s quiet period expired on Tuesday, November 5th. (BIOA) had issued 11,000,000 shares in its public offering on September 26th. The total size of the offering was $198,000,000 based on an initial share price of $18.00. During (BIOA)'s quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are (BIOA)'s major shareholders?

(BIOA)'s top institutional investors include AH Capital Management L.L.C. (8.41%), RA Capital Management L.P. (6.17%), Suvretta Capital Management LLC (4.06%) and RTW Investments LP (2.19%).
View institutional ownership trends.

What other stocks do shareholders of (BIOA) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (BIOA) investors own include ProQR Therapeutics (PRQR), Flexion Therapeutics (FLXN), Rite Aid (RAD), LadRx (CYTR), Intellipharmaceutics International (IPCIF), NVIDIA (NVDA) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 8/09/2016
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/06/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NYSE:BIOA
• CUSIP: N/A
• CIK: 1534287
• Web: www.bio-amber.com
• Phone: +1-612-7474423
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $42.33
• High Stock Price Target: $45.00
• Low Stock Price Target: $40.00
• Potential Upside/Downside: +130.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,850,000
• Free Float: N/A
• Market Cap: $659.64 million
• Optionable: Not Optionable
• Beta: N/A